Memento Medicines

Founded 2025 · CIK 0002139514 · Biotech · Private

Biologic molecules that modulate multiple pathways to treat retinal diseases

globenewswire.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$38M
1 Form D · Jun 2026
4 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$38,000,159
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2347MEDICON, INC.——
2348THYMMUNE THERAPEUTICS INC——
2349OmniTier, Inc.—$4.0M
2350Memento Medicines—$38M
2351WindMIL Therapeutics—$45M
2352Illuminare Biotechnologies Inc—$6.0M
2353Ostentus Therapeutics, Inc.—$1.8M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • William BonificioExecutive Officer · Promoter
  • Naveen DaryaniDirector · Executive Officer · Promoter
  • Dmitrij HristodorovDirector
  • Vishal KapoorDirector
  • Megan KrenchDirector
  • Zach ScheinerDirector
  • Stephen ThomasExecutive Officer · Promoter

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.